In the present study, we demonstrate that hepatic ADAR2 is downregulated in NAFLD mice, while exercise protects the liver from hepatic steatosis via the upregulation of ADAR2. Our study further shows that ADAR2 participates in the lipogenesis in HepG2 cells by targeting miR-34a, which is a crucial regulator of lipid metabolism. This research provides compelling evidence that increasing ADAR2 might be a potential strategy for managing NAFLD.
2. Materials and Methods 2.1. Animals and TreatmentsMale C57BL/6 wild-type mice that were 8 weeks old were obtained from SLAC Laboratory Animal Company (Shanghai, China). The animals used in the study were housed on a 12 h light/dark cycle at 25 °C and were provided with free access to commercial rodent chow and tap water or to a high-fat diet (HFD) and Nω-nitro-L-arginine methyl ester, hydrochloride (L-NAME) for 12 weeks, a NOS inhibitor, which was shown to exacerbates liver injury in an obese rodent model of NAFLD [32]. The HFD was a rodent diet with 60 kcal% fat (D1249, Research Diet, New Brunswick, NJ, USA). L-NAME was dissolved in drinking water at a concentration of 0.5 g/L (N5751, Sigma-Aldrich, St. Louis, MO, USA). Mice were randomized into four groups: (i) control group, mice fed with standard chow and tap water; (ii) exercise groups, mice fed with standard chow and tap water and subjected to exercise; (iii) HFD and L-NAME diet group, mice fed with HFD and L-NAME; and (iv) HFD and L-NAME diet and exercise group. Each group contained 6 mice, and we used 24 mice in total in the research. The exercise plan was implemented as previously described [28,33]. The exercise mice were put on a treadmill that was specially designed for mice. The running training began at 5 m/min for 10 min with a speed and time increase of 2 m/min and 10 min each day. By the end of the experiment, the mice had been running at the speed of 15 m/min for 60 min for a period of 12 weeks. All training sessions were held at the same time each day to avoid effects on training performance. After the 12-week feed and exercise program, all animals were anesthetized and sacrificed. Liver tissues were isolated and snap-frozen for future analysis or were put into 4% paraformaldehyde buffer (PFA) immediately for histological study. All animal experiments were reviewed and approved by the Animal Ethics Commission of Shanghai Tongji Hospital, Tongji University School of Medicine (2021-DW-007). 2.2. Histological AnalysisHistological hematoxylin–eosin (H&E) staining and Oil Red O staining were used to elevate the lipid composition in the liver. Liver tissues from the mouse were cut into 4 μM sections for H&E staining after being fixed in 4% PFA and embedded in paraffin. Frozen 4 μM liver sections were washed with 60% isopropyl alcohol and then stained with Oli Red O solution for 8 min. Hematoxylin was used to stain the nucleus for 2 min. Finally, the sections were mounted using glycerol jelly as the mounting medium. Images were obtained using a microscope (Leica, Wetzlar, Germany).
2.3. Cell Culture and TreatmentCells from human hepatocellular cancer cell line HepG2 were acquired from FuHeng Cell Center (Shanghai, China). High-glucose DMEM (Hyclone, Logan, UT, USA) containing 10% fetal bovine serum (Thermo Fisher, Waltham, MA, USA) and 1% penicillin/streptomycin was used as a growth medium for HepG2 cell cultures. The cell cultures were maintained under standard conditions (37 °C, humidified atmosphere, 5% CO2). Oleic acid (OA) was bought from Sigma. HepG2 cells were treated with a medium containing 250 μM OA for 24 h to induce lipogenesis in vitro.
2.4. Vector ConstructionFor the overexpression of human ADAR2, the coding region of human ADAR2 was obtained from the National Center for Biotechnology Information (NCBI). Gene fragments were generated by PCR amplification and cloned into FUGW. Finally, the fragments were verified using Sanger sequencing. The following PCR primers were used:
humanADAR2 Forward Primer:
5′-GGGACCGGTATGGATATAGAAGATGAAGAAAA-3′
humanADAR2 Reverse Primer:
5′-CCGGAATTCTCAGGGCGTGAGTGA-3′
Short interfering RNAs (siRNAs) were purchased from Hanbio Biotechnology (Shanghai, China).
2.5. Vector TransfectionHepG2 cells were precultured in serum-free media overnight, 8 h before transfection. MiR-34a inhibitor (100 nM), mimic (50 nM), and negative controls (RiboBio, Guangzhou China) as well as ADAR2 overexpression plasmid and ADAR2 siRNA were all transfected for 48 h using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions.
2.6. Nile Red StainingNile Red staining was used to assess lipid droplet formation in cells. HepG2 cells were seeded in 24-well plates and treated with OA for 24 h (250 μM). After being washed with PBS, the cells were fixed with 4% PFA for 15 min at room temperature. Then, the cells were stained with Nile Red solution (0.1 mM) for 15 min. Cell nuclei were stained with DAPI (Peprotech, Rocky Hill, NJ, USA) for 15 min. The entire staining process was carried out away from light.
2.7. Quantification of TGsTriglycerides (TGs) were measured according to the instructions of the assay kit (Nanjing Jiancheng Bioengineering Institute, China). TGs can be catalyzed to red quinones under the guidance of instruction. The color of the quinones is proportional to the level of TG. The protein concentrations were measured using the BCA protein assay kit (KeyGEN, China). The lipid content was calculated according to the lipid level/protein concentration.
2.8. Real-Time Quantitative PCRTotal RNA was extracted using Trizol (Invitrogen, Waltham, MA, USA) and then used for cDNA synthesis according to the instructions (TaKaRa, Kusatsu, Japan). cDNA was used as the template for qRT-PCR using SYBR-Green (TaKaRa, Japan). GAPDH was used as an internal control. The expression of miR-34a was detected by the Bulge-LoopTM miRNA qPCR Primer Set (RiboBio, Guangzhou, China) with SYBR-Green (TaKaRa, Japan) by qRT-PCR. U6 (RiboBio, Guangzhou, China) was used as the internal control for miR-34a. The relative expression levels of the genes were calculated using the 2−ΔΔCt method. The sequences of the primers used in the study are shown in Table S1. 2.9. Western Blot AnalysisProteins from the liver tissues were collected using RIPA buffer (Thermo Fisher Scientific, Waltham, MA, USA). The protein concentration was elevated using the BCA Protein Assay Kit. Total proteins were separated with 10% SDS-PAGE gels, transferred into PVDF membranes, and incubated with the primary antibodies at 4 ℃ overnight. The primary antibodies were as follows: ADAR2 (diluted 1:1000; A16748, ABclonal, Wuhan, China) and β-actin (diluted 1:100,000; AC026, ABclonal, Wuhan, China). After incubation with the secondary antibody, the proteins were visualized using a luminescent imaging system (BioRad, Hercules, CA, USA) and enhanced using the ECL Chemiluminescent Kit (Thermo Pierce, Waltham, MA, USA). The analysis of the protein bands was carried out using Image J software.
2.10. Statistical AnalysisThe data in the paper are presented as means ± SDs. Either a t-test or two-way analysis of variance was performed on the samples to assess significant differences using GraphPad Prism version 7.0. A p value of < 0.05 was considered statistically different.
4. DiscussionNAFLD is a metabolic stress-induced liver injury that is closely related to insulin resistance and genetic predisposition and that can lead to liver injury, cirrhosis, and other death-related chronic liver diseases. Moreover, NAFLD is also closely associated with the high incidence of metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM), arteriosclerotic cardiovascular disease, and colorectal tumors [36]. Due to the complicated molecular regulatory mechanism of NAFLD, there is still no specific treatment for NAFLD [37]. Lifestyle interventions such as exercise can promote the healthy state of NAFLD patients [38]. In our study, we demonstrate that hepatic steatosis in NAFLD mice induced by diet is significantly attenuated by aerobic exercise. Hepatic ADAR2 is downregulated in NAFLD mice, and it can be restored via aerobic exercise. The in vitro findings suggest that the elevation of ADAR2 reduces lipogenesis in HepG2 cells, while the decrease of ADAR2 drives lipogenesis induced by free fatty acids. Finally, we show that ADAR2 contributes to lipogenesis by targeting miR-34a during NAFLD development.It is clear that lifestyle interventions are beneficial for NAFLD, especially for individuals with obesity, as recommended in clinical practice and supported by high-quality evidence [6]. Compared with drug treatment, exercise is a cost-effective intervention for both patients and susceptible populations with risk factors [6]. Some studies have shown that exercise cannot only recover serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), but can also lower the hepatic lipid content, whether the exercise intervention is aerobic training, resistance training, or hybrid and acceleration training [38]. Aerobic exercise is an efficient means of alleviating NAFLD in mice and has been confirmed in animal models by several studies, and our previous study essentially showed the same result [28]. Different from high-intensity exercise training, aerobic exercise does not require prior adaptive training. [39]. Reducing intrahepatic lipid content may be one possible mechanism to alleviate NAFLD via exercise [38]. For example, exercise was able to reduce hepatic lipogenesis [40,41]. HFD combined with L-NAME was used to establish the NAFLD mice model, as previously described, representing a compound- and diet-induced NAFLD model [42]. L-NAME, the NOS inhibitor, can promote hepatic TG and cholesterol by regulating the metabolism of TG synthesis and cholesterol [32,43]. Typical manifestations of NAFLD have been found in mice, including body weight gain, liver weight gain, and improved liver steatosis. We trained the mice with moderate-intensity aerobic exercise. In our work, we found that exercise could attenuate the body weight and liver weight of mice. Moreover, exercise training significantly decreased intrahepatic lipid accumulation by reducing lipid synthesis in NAFLD mice.The ADAR activity during A-to-I editing was considered due to its unique function on the diversity of RNA and protein to both coding and non-coding RNA [44]. It has been reported that ADAR1 plays a vital role in hepatic immune homeostasis, hepatocellular carcinoma, and adipogenesis [45,46,47]. ADAR2 is another member of the adenosine deaminase family. However, the influence of ADAR2 in lipogenesis, especially in NAFLD, is still unknown. Our results indicated that ADAR2 was downregulated in the livers of NAFLD mice, and that exercise resulted in an obvious reversal in the ADAR2 level, which is synchronous with the process of lipid accumulation and dissipation in the liver observed in the histology results. Then, we used a HepG2 cell model with OA treatment to further clarify the functional and molecular mechanisms of ADAR2 in lipid metabolism. Overexpression of ADAR2 in HepG2 cells could inhibit lipid generation, with a decrease in intracellular lipid droplets and the expression of lipogenesis-related genes. By contrast, the knockdown of ADAR2 promotes lipogenesis with elevated lipid accumulation in the adipocytes. The levels of TG in HepG2 cells were also decreased under the overexpression of ADAR2 compared to the OA treatment, while the inhibition of ADAR2 has the opposite effect. Together, we exposed the crucial role of ADAR2 in hepatic lipogenesis, which indicates that ADAR2 has the potential to be used as an exercise-related therapeutic target for NAFLD. Notably, the optimal exercise intensity and duration for interventions for metabolism-related diseases remains controversial. In our study, we explored the possible mechanism of ADAR2 in moderate-intensity exercise, but whether there are differences in the role of ADAR2 regarding different exercise prescriptions still needs elucidation by further research.A-to-I editing is an abundant RNA modification that takes place in miRNA through ADARs. It plays a regulatory role in multiple processes, from miRNA generation to function. First, ADARs edit pri-miRNA or pre-miRNA to further influence the synthesis of mature miRNA because of their hairpin structures [48]. Moreover, A-to-I editing influences miRNA target recognition in mature miRNA [48]. Then, we identified the candidates of ADAR2 in the progression of NAFLD. First, we found a significant increase in the miR-34a in the liver of HFD-induced NAFLD mice in our previous research, and exercise reduced the expression of miR-34a [28]. At the same time, exercise-induced ADAR2 protected the heart from myocardial infarction and doxorubicin-induced cardiotoxicity via miR-34a in cardiomyocytes [21]. Three nucleotide sites of pri-miR-34a were changed after ADAR2 overexpression. In detail, U44-C and A61-G are two major editing sites of pri-miR-34a, and A72-G is a minor site in the antisense strand of pri-miR-34a. Moreover, ADAR2 overexpression changes the RT-PCR product of pri-miR-34a in cardiomyocytes, which further implies the RNA editing of pri-miR-34a [21]. To define the relationship between ADAR2 and miR-34a in NAFLD, we found that ADAR2 can negatively regulate the expression of miR-34a in vitro, regardless of OA treatment. Interestingly, in the mice models, we also showed that the miR-34a level in NAFLD mice was decreased. In contrast, a reversed miR-34a level was spotted in exercised NAFLD mice compared to in sedentary NAFLD mice, which further indirectly suggests that ADAR2 may change the expression levels of miR-34a inversely. Furthermore, miR-34a mimic was able to abolish the lipogenesis-reducing effect of ADAR2 overexpression in HepG2 cells. Overall, ADAR2 exerted its effect on lipogenesis by targeting miR-34a.As a post-transcriptional regulator with extensive functions, miRNA has been confirmed to participate in the NAFLD process. Elevated levels of miR-34a were reported in both NAFLD and nonalcoholic steatohepatitis (NASH) mice in previous studies [49,50]. miR-34a can regulate liver steatosis by inhibiting very low-density lipoprotein secretion and by promoting hepatic oxidative stress and inflammation through different molecular structures such as hepatocyte nuclear factor 4, alpha (HNF4α), sirtuin1 (Sirt1), and cyclin-dependent kinase 6 (CDK6) [34,35,51]. Hepatic miR-34a expression was also increased in the serum of NAFLD and NASH patients [52]. In our work, we found that miR-34a played a crucial role in the development of NAFLD under the regulation of ADAR2. miR-34a inhibitor was capable of inhibiting lipogenesis with the decreased triglyceride accumulation in HepG2 cells, while miR-34a mimic was able to promote lipogenesis via the enhanced triglyceride accumulation in HepG2 cells in the presence of OA treatment.To completely prove that ADAR2 contributes to the protective effect of NAFLD via regulating miR-34a as key molecules generated by exercise, further study is required to carry out in vivo research in mice and is required to evaluate the effect of ADAR2 as a therapeutic method for NAFLD. The expression of ADAR2 and its target mRNA/miRNA in human samples also requires further clarification. This could advance our understanding of ADAR2 in NAFLD development.
In conclusion, exercise-induced ADAR2 growth attenuates NAFLD development by decreasing the level of miR-34a. We provide experimental evidence that ADAR2 may present a potential therapeutic target of NAFLD.
Comments (0)